Closed Loop Medicine Ltd.

LONDON--( BUSINESS WIRE )--Closed Loop Medicine Ltd., a leading TechBio company leveraging AI, machine learning, and personalized dosing to enhance drug development, today announced the appointment of Luba Greenwood as Chair of its Board of Directors. Luba is a distinguished executive and investor with over 20 years’ experience in healthcare and tech. She has led over $10 billion USD in deals and investment over multiple therapeutic areas, leading success and scaling companies across the life sciences, medical devices, diagnostics, and tech sectors, including co-founding biotech and digital companies in the immunotherapy, women’s health, AI/ML and microbiome space. Leveraging broad corporate experience alongside legal and technical expertise, Luba’s appointment to Closed Loop Medicine’s Board will be instrumental in supporting development of the Company’s partnering and growth outside of the UK. Luba is currently the Managing Partner of Binney Street Capital (BSC), a venture fund she founded at the Dana-Farber Cancer Institute and has previously served as CEO and Chair of Kojin Therapeutics, a company developing small-molecule therapeutics for a wide range of diseases. She has previously held leadership roles at Google Life Sciences (Verily) and as Vice President of Global Business Development and M&A at Roche, where she established the East Coast Innovation Hub. Luba is a former lawyer with deep understanding of corporate governance and regulatory, policy, and intellectual property across the pharmaceutical, biotechnology, and technology industries. Luba has served on the Boards and as an advisor to numerous private and publicly-traded companies, including Abcam, spearheading the sale to Danaher in 2023, and the non-profit Massachusetts Biotechnology Council (MassBio). The news follows in a series of high-profile appointments to Closed Loop Medicine’s Board, including digital healthcare leader, Paul Johnson , founder and former CEO of Lemonaid Health, as Non-Executive Director in May 2024, and David Van Sickle , former CEO and Co-Founder of Propeller Health, a digital health and medtech company that launched one of the first integrated software and device combination interventions transforming respiratory disease. Luba’s appointment as Chair demonstrates another integral stage in the Company’s strategy as it prepares for breakthrough milestones in the progression and commercialization of its product pipeline. Luba Greenwood, Chair of the Board of Closed Loop Medicine, commented: “ By catalyzing the development of more precise therapeutics across vast disease areas, Closed Loop’s platform has the potential to not only improve drug safety and efficacy, but transform the way healthcare is delivered.” She added: “ The work I do—and have been doing—has been driven by my dedication to bringing innovative products to market and ultimately to patients. I’m excited to be a part of the Company’s pioneering journey for better medicines, alongside a very impressive Board of Directors, to bring precision medicines to all patients in need. ” Hakim Yadi PhD OBE, CEO & Co-Founder of Closed Loop Medicine, said: “ On behalf of the entire team at Closed Loop, I am delighted to welcome Luba as Chair of our Board. Her impressive background and expertise in healthcare and tech, particularly as it pertains to the US market, will be instrumental in bolstering the Company’s strategic growth. With her strong track-record of building world-class teams and companies, we are well-positioned for the commercialization of our products and the expansion of our partnerships.”

According to the company, about one in five patients do not refill their first prescription of Pfizer’s first-line blood pressure med Norvasc, largely due to dose-dependent side effects such as swelling of the legs and ankles. Closed Loop’s smartphone app aims to help dial in the correct amount on a per-person basis, built on patient-submitted reports. The precision medicine developer Closed Loop Medicine has put forward a study showing that its approach of combining prescription drugs with dose-optimizing software could help personalize the treatment of high blood pressure. The Cambridge, U.K.-based company said its digital therapeutic companion could help not only to boost patient adherence to medication, but also to demonstrate clinically significant gains against hypertension in a short amount of time.  Closed Loop described the results as a stepping stone to broader platforms, which could include other pharmaceuticals such as GLP-1s for diabetes and weight loss. The company has also been studying its programs in insomnia. The study, published in the Journal of the American Heart Association, examined a pilot for remote care management during the COVID-19 pandemic. Closed Loop’s combination treatment, dubbed CLM-HT01, pairs the company’s app with Pfizer’s first-line blood pressure med Norvasc (amlodipine). According to the company, about one in five patients do not refill their first prescription of the drug, largely due to dose-dependent side effects such as swelling of the legs and ankles. Closed Loop’s smartphone app aims to help dial in the correct amount on a per-person basis, built on patient-submitted reports. “Often starting with very small doses, empowering participants to share both wanted and unwanted effects of medication helped us to work together to reduce blood pressure while minimizing any side effects,” said the study’s lead investigator, David Collier, a clinical director at Queen Mary University of London. “Some participants who had never tolerated full doses of any blood pressure medication got control for the first time.” The 14-week trial of about 200 participants showed that average home blood pressure readings fell from 142/87 mmHg to 131/81 mmHg—with about one-third of patients demonstrating control with the study’s lowest amlodipine dose, titrated to 1 mg per day. About 88% were able to control their hypertension with no peripheral edema, while adherence rates in blood pressure recording and medication were 84% and 94%, respectively. “To improve patient outcomes, we need to shift to a world where we treat the individual, not just the disease,” Closed Loop’s co-founder and CEO, Hakim Yadi, said in a statement.  “These findings are invaluable in demonstrating the power of personalizing the dose of existing therapeutics in areas as widely impactful as hypertension,” Yadi added. “We now want to take these learnings and apply them more broadly where we feel they will have the most impact, for example to minimize the adverse effects limiting GLP-1 programmes—an area currently seeing huge attention.”

Study published in JAHA validates use of proprietary technology to identify personalized dose regimen, leading to improved blood pressure control and exceptionally high adherence in hypertension patients Findings will guide the Company’s strategy to expand portfolio of differentiated dose-optimized therapies, including within GLP-1 market LONDON--(BUSINESS WIRE)-- Closed Loop Medicine Ltd., a leading TechBio company developing combination prescription drug plus software therapy products that deliver personalized dose optimization, today announced the publication of a peer-reviewed study in the Journal of the American Heart Association (JAHA) (1). The study describes results of the PERSONAL-CovidBP clinical trial; demonstrating the capabilities of the Company’s integrated precision care solution, CLM-HT01, to successfully control blood pressure (BP) whilst minimizing side effects and supporting medication adherence in participants with primary hypertension. The findings will be applied to drive further development of CLM-HT01 and the Company’s extended pipeline of combination products in other therapeutic areas, aiming to deliver precision dosing at population scale. Hypertension is the leading preventable cause of morbidity and premature death worldwide. Despite being a first-line recommended anti-hypertensive drug, ~20% of patients discontinue amlodipine after a single prescription largely due to unwanted effects, such as peripheral oedema, which is strongly dependent on dose. CLM-HT01 is a single label combination product in development, linking Closed Loop Medicine’s proprietary software as a medical device (SaMD) with amlodipine, designed to support more effective, precise, and affordable disease management solutions to improve outcomes for patients and streamline clinician input. The study “Personalized antihypertensive treatment optimization with smartphone-enabled remote precision dosing of amlodipine during the COVID-19 pandemic” reinforces the ability to use a digital companion alongside traditional therapeutics to optimize clinical outcomes. This was achieved by adjusting and personalizing drug dosing using information recorded by participants into a dedicated smartphone app and transmitted securely to a clinician. Clinically significant reductions in BP were rapidly observed, with the majority of participants achieving BP control and minimizing side effects, including those previously intolerant of conventional amlodipine doses. High adherence rates were reported (both app usage and medication) and patient retention was exceptionally high with no discontinuations due to drug intolerance. The findings build on preliminary results published in the Journal of the American College of Cardiology (2) and the Journal of Human Hypertension (3). Dr. Hakim Yadi OBE, CEO & Co-Founder of Closed Loop Medicine, commented: “These findings are invaluable in demonstrating the power of personalizing the dose of existing therapeutics in areas as widely impactful as hypertension. We now want to take these learnings and apply them more broadly where we feel they will have the most impact, for example to minimize the adverse effects limiting GLP-1 programmes – an area currently seeing huge attention.” He added: “To improve patient outcomes, we need to shift to a world where we treat the individual, not just the disease. Our inventions will work in combination with medicine to deliver personalized, optimized dosing; improving human health.” Dr. David Collier, the lead trial investigator from Queen Mary University of London, said: “We are incredibly pleased to have the final results from the PERSONAL-CovidBP trial published in the JAHA, a leading open access scientific journal.” He added: “We wanted to use personalized dosing of amlodipine, and had worked with our patients to develop a digital platform to allow this. Working remotely due to COVID we still managed to recruit, triage (selected participants according to home blood pressure), and then treat patients with this novel approach. Often starting with very small doses, empowering participants to share both wanted and unwanted effects of medication helped us to work together to reduce blood pressure while minimizing any side-effects. Some participants who had never tolerated full doses of any blood pressure medication got control for the first time.” Dr. Mike Taylor, Senior Vice President Clinical Development of Closed Loop Medicine, added: “Data generated in this study in hypertension demonstrate significant benefits offered by precision dose titration enabled by a dedicated smart phone app. This novel technology enables clinicians to efficiently personalize and optimize therapy routines for patients, leading to improved health outcomes by finding a better balance between efficacy and unwanted effects. Daily self-monitoring and side effect reporting empowers patients through a more comprehensive understanding of how medication impacts overall wellbeing, whilst providing more peace of mind knowing that a clinician is able to assess changes in real-time and optimize the tolerability and efficacy of said drug treatment.” PERSONAL-CovidBP was part-funded by Innovate UK and run by the William Harvey Clinical Research Centre at Queen Mary University of London, part of the National Institute for Health Research Biomedical Research Centre at Barts NHS Trust in London. Collier D et al. 2024. Taylor M et al. 2022. (22)02988-6 Collier D et al. 2022. View source version on businesswire.com: Contacts Lily Jeffery lily.jeffery@zymecommunications.com Source: Closed Loop Medicine View this news release online at: